• Min Cheol Chang and Donghwi Park.
• Department of Rehabilitation Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.
• Medicine (Baltimore). 2021 Dec 3; 100 (48): e27791.

RationaleThe α-amino-3-hydroxy-5-methy-4-isoxazole propionate (AMPA) receptor plays a critical role in the development and persistence of pain, and AMPA receptor antagonists are considered possible therapeutic targets for controlling pain. This report describes a patient with complex regional pain syndrome (CRPS) type I in the right lower leg and foot who responded well to perampanel, an AMPA receptor antagonist, for managing the chronic pain.Patient ConcernA 61-year-old woman complained of pain in her right lower leg and foot over a period of 7 year (numeric rating scale: 8) due to CRPS type I.DiagnosisCRPS type 1.InterventionsDespite the combination of 300 mg pregabalin, 225 mg/1950 mg tramadol/acetaminophen, and 10 mg nortriptyline per day, her right lower leg and foot were nearly disabled due to the severity of the pain. High-dose prednisolone was found to be ineffective. Then, perampanel (4 mg; 2 mg twice) was administered to this patient daily.OutcomesThe day after treatment with perampanel, her pain completely disappeared. Additionally, at day 7 and 1 month follow-up, she reported no pain in the right lower leg and foot. Moreover, no adverse effects were reported after the application of perampanel.LessonsThese results suggest that perampanel may potentially be used to treat centralized pain.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

26 keywords...

hide…